氘可来昔替尼(Deucravacitinib)价格多少钱一盒？

Deuterated colexitinib (deucravacitinib) can be used to treat plaque psoriasis. It has been launched in the United States in September 2022. Deuterated colexitinib has not yet been launched in China, and no price has been announced. In the overseas market, the price of deucravacitinib (deucravacitinib) from Bangladesh Ziska Pharmaceutical Factory Deucrava (direct mail from Bangladesh) is 550$ per box, and the specification is 6mgx30 tablets.

How much does Deucravacitinib cost per month?

Deucravacitinib is recommended as 6 mg (one tablet), taken orally once daily, with or without food. Do not crush, cut, or chew tablets. That is to say, it costs exactly one box of Deucravacitinib every month. Patients can also calculate the required cost based on their own circumstances.

Patients who need Deucravacitinib can purchase it abroad, but the cost will be relatively high and the purchase is not guaranteed. Patients can also obtain it through domestic professional overseas medical service institutions. The drugs can be directly mailed to their homes from overseas. They are guaranteed to be authentic and at affordable prices. However, the price of overseas drugs is not fixed due to exchange rate fluctuations. It is recommended to consult customer service staff for specific costs and acquisition procedures.

What are the effects of Deucravacitinib?

Deucravacitinib is an oral highly selective TYK2 (tyrosine kinase 2 allosteric inhibitor) that binds to the more heterogeneous JH2 domain of TYK2 and achieves precise targeted inhibition of TYK2 by changing the conformation of its active domain. Make treatment more precise and medication safer. (Deucravacitinib) is the first innovation in the oral treatment of moderate to severe plaque psoriasis in the past 10 years.

POETYK PSO-3, the first Asian multi-center psoriasis phase III clinical study mainly in China, showed that among all psoriasis patients randomized to the deuterated colexitinib treatment group: 68.8% of psoriasis patients successfully achieved PASI at week 16 of using deuterated colexitinib. 75 (the psoriasis area and severity index improved by at least 75%), which was significantly better than the placebo group (8.1%), and the overall safety and tolerability were good. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Recommended hot articles: